By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cantargia 

Medicon Village
Scheelevägen 2
  Lund  SE-223 81  Sweden
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Cantargia Obtains A Granted Patent From USPTO Concerning Il1RAP In Solid Tumors 7/15/2016 11:12:31 AM
Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Solid Tumors 6/10/2016 8:34:56 AM
Cantargia'’s CAN04 Product Candidate Show Very Good Safety At High Dose Levels, Paving The Way For Final GLP Toxicity Study In Autumn 2016 6/10/2016 7:57:56 AM
Cantargia Receives Patent Approval In Japan For Solid Tumors 6/8/2016 10:55:10 AM
Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Acute Lymphatic Leukemia 6/8/2016 10:53:05 AM
Cantargia Interim Report January – March 2016 5/16/2016 9:46:10 AM
Cantargia Raises SEK 31.4 Million Through Exercise Of Warrants Of Series TO 1 And TO 3 4/20/2016 11:44:46 AM
Cantargia Receives Patent Approval In Japan And Mexico 3/21/2016 10:59:12 AM
Cantargia Secures Exercise Of Warrants Of Series TO 1 3/10/2016 10:34:18 AM
Cantargia’s CAN04 Product Candidate Shows Good Safety After Repeated Doses In New Toxicity Study 3/9/2016 10:59:30 AM
12
//-->